FDA to hold adcomm for Grail cancer test that failed in large, randomized trial

FDA Schedules Advisory Committee Meeting for Grail's Galleri Multi-Cancer Screening Test

The U.S. Food and Drug Administration will convene its Molecular and Clinical Genetics Panel on September 23, 2026, to review Grail's premarket approval application for Galleri, a multi-cancer early detection test. The advisory committee meeting represents a critical regulatory milestone for the company, which anticipates a potential approval decision in early 2027.